Central venous catheters may harm patients

Central venous catheters are commonly used to provide permanent hemodialysis for patients with serious kidney disease.

One technique, inserting a catheter through large vessels, has been commonly used worldwide in recent years. A new study published in Hemodialysis International finds that this treatment may block the blood flow in the vessel, leading to superior vena cava syndrome (SVC syndrome), a highly serious complication caused by the obstruction of blood coming to the heart from the upper body.

The warning signs of SVC syndrome include shortness of breath, swelling of the upper limbs, neck and face, which occur as the catheter, generally inserted into a large blood vessel, blocks blood flow. The study stresses the need for clinicians to be able to identify SVC syndrome symptoms in order to prevent more serious complications.

“The increasing use of central vein catheters for long-term hemodialysis has contributed high rates of complications,” concludes Hadim Akoglu, M.D., author of the study. “It seems that SVC syndrome due to central vein catheters will become an important threat as the popularity of this treatment continues to grow.”

Akoglu suggests that the harmful effects of SVC syndrome can be counteracted if catheters are only used for short periods of time. Treatments for SVC syndrome are also being devised, including thrombolytic therapy, where blood clots are pharmacologically dissolved; percutaneous transluminal balloon angioplasty (PTA); intravascular stent placement; and surgical reconstruction, which re-opens blood flow access in the vessel.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients